Report from the International Union Against Cancer (UICC) Tumor Biology Committee

A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

1973 • 4,217 citations

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

1996 • 1,854 citations

Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

1990 • 1,305 citations

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1995 • 1,097 citations

Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia

1994 • 592 citations

Dendritic Cell Vaccines for Cancer Immunotherapy

1999 • 497 citations

Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial

1997 • 464 citations

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

1998 • 403 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

Migration of human dendritic cells after injection in patients with metastatic malignancies.

1999 • 353 citations

Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

1997 • 309 citations

Chronic myelogenous leukemia in blast crisis

1987 • 283 citations

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1998 • 246 citations

CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS

1999 • 245 citations

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1999 • 242 citations

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

1995 • 213 citations

T-cell immunity to the joining region of p210BCR-ABL protein.

1992 • 184 citations

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1997 • 163 citations

Dendritic cells : biology and clinical applications

1999 • 151 citations

Dendritic Cells: Biology and Clinical Applications

1999 • 139 citations

Dendritic Cells Stimulate the Expansion of bcr-abl Specific CD8+ T Cells With Cytotoxic Activity Against Leukemic Cells From Patients With Chronic Myeloid Leukemia

1998 • 133 citations

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

1997 • 126 citations

Treatment of chronic myeloid leukemia by marrow transplantation [editorial; comment] [see comments]

1993 • 118 citations

BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors

1996 • 115 citations

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

1998 • 113 citations

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study

1996 • 112 citations

Rapid Extracellular Degradation of Synthetic Class I Peptides by Human Dendritic Cells

1998 • 106 citations

Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.

1995 • 106 citations

HLA-DR1–Restricted bcr-abl (b3a2)-Specific CD4+ T Lymphocytes Respond to Dendritic Cells Pulsed With b3a2 Peptide and Antigen-Presenting Cells Exposed to b3a2 Containing Cell Lysates

1997 • 105 citations

Response criteria for the prostate of the USA national prostatic cancer project

1980 • 97 citations

Treatment of chronic myeloid leukemia by marrow transplantation [editorial; comment] [see comments]

1993 • 95 citations

Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells

1997 • 93 citations

Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation

1998 • 89 citations

HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration

1988 • 78 citations

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

1998 • 67 citations

The use of dendritic cells for cancer vaccination.

1999 • 58 citations

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

1995 • 51 citations

Induction of Primary,Human Antigen-Specific Cytotoxic T Lymphocytes In Vitro Using Dendritic Cells Pulsed with Peptides

1998 • 48 citations

Autografting in chronic myeloidleukaemia

1994 • 18 citations

Dendritic cell-based approaches to cancer immunotherapy

1998 • 4 citations